ArticleBMC research notes2026
Biomarkers and immunomodulatory effect of erythropoietin in postoperative ileus.
Article in BMC research notes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectivePostoperative ileus (POI) is a type of intestinal motility disorder (IMD) that can occur after abdominal surgery. At present, there is no accepted treatment for POI and no reliable biomarkers to assess the status of POI. Erythropoietin (EPO) can promote the recovery of the intestine from various injuries, including POI. This study aimed to investigate the immunomodulatory role of EPO and to identify reliable biomarkers of POI.
resultsThe computational analysis suggested that immune signaling via EPO/EPOR pathways may vary in POI. Luminex multiplex analysis showed that EPO treatment considerably altered intestinal tissue pro-inflammatory (CRP, IL6, IL12p70, IL12p40, IL2, and IFNγ) and anti-inflammatory (IL4, IL10, and IL13) cytokines. EPO decreased pro-inflammatory intestinal chemokines (CCL12, CXCL2, and CCL4) and serum IL6, CRP, and CCL12 following POI. IL6, CRP, and CCL12 may serve as promising biomarkers for POI in both tissue and serum samples. The gene expression analysis of these markers confirmed their significance with increased levels in intestinal tissue of POI, and EPO treatment caused attenuation.
conclusionsTo our knowledge, this is the first study to investigate the immunomodulatory effect of EPO following IM, and suggests CCL12, CRP, and IL6 as reliable biomarkers of POI in both intestinal and serum samples.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.